Mineralys Therapeutics (MLYS) Depreciation & Amortization (CF) (2024 - 2026)
Mineralys Therapeutics (MLYS) reported Depreciation & Amortization (CF) of $6000.0 for Q1 2026, down 60.0% on a YoY basis from $15000.0 in Q1 2025, and down 53.85% sequentially from $13000.0 in Q4 2025.
Mineralys Therapeutics (MLYS) Depreciation & Amortization (CF) (2024 - 2026) Analysis & Trends
Mineralys Therapeutics (MLYS) has 3 years of Depreciation & Amortization (CF) data on file, last reported at $6000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 60.0% year-over-year to $6000.0; the trailing twelve-month figure through Mar 2026 stood at $50000.0 (changed 0.0% YoY), and the FY2025 full-year result was $59000.0, up 37.21% from the prior year.
- Depreciation & Amortization (CF) eased to $6000.0 in Q1 2026, from $13000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $16000.0 in Q2 2025 to a low of $6000.0 in Q1 2026.
- A 3-year average of $12000.0 and a median of $13000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) surged 87.5% in 2025 and slumped 60.0% in 2026, its largest moves.
- Tracing MLYS's Depreciation & Amortization (CF) over 3 years: stood at $15000.0 in 2024, then decreased by 13.33% to $13000.0 in 2025, then plunged by 53.85% to $6000.0 in 2026.
- Business Quant data shows MLYS's Depreciation & Amortization (CF) at $6000.0 in Q1 2026, $13000.0 in Q4 2025, and $15000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Mineralys Therapeutics | 2.24 Bn | 2.24 Bn | - | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Jun 30, 2025 | 16,000.00 |
| Jun 30, 2025 | 16,000.00 |
| Mar 31, 2025 | 15,000.00 |
| Mar 31, 2025 | 15,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Sep 30, 2024 | 11,000.00 |
| Sep 30, 2024 | 11,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Mar 31, 2024 | 8,000.00 |